Public advisory - Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection
OTTAWA, ON, July 7, 2023 /CNW/ -
Summary
Product: Rhinaris Nasal Mist 30 mL (lot 230391A)
Issue: Health products - Product safety
What to do: Do not use the affected product. Return it to your local pharmacy for proper disposal.
Images
Affected products
Product
DIN
Lot
Expiry date
UPC
Rhinaris Nasal Mist 30 mL
02354551
230391A
31-05-2025
5760622302
Issue
The Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.
Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages in adults and children at least two years of age.
The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.
Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).
While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.
What you should do
Do not use the affected product. Return it to your local pharmacy for proper disposal.
Consult a health care professional if you have used this product and have health concerns.
Contact Pendopharm Division of Pharmascience Inc. by calling 1-888-550-6060 or emailing [email protected] if you have questions about this recall.
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate's drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress,...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio...
America's child care supply remains flat, while child care prices continue to increase, according to a new report released today by Child Care Aware® of America (CCAoA) that highlights the burden families face accessing quality and affordable child...
The cost of living is Gen Zs' and millennials' top societal concern, but green shoots of optimism for the economy and their personal finances are emergingNearly nine in 10 Gen Zs and millennials say purpose is important to their job satisfaction and...
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. ...
BioArctic AB's (publ) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net...